David,
Hiring a good PR/IR firm is not like using a magic wand. Once a company increases its IR efforts, its stock won't just jump 50%. IR work is a long term and ongoing job - meeting analysts, money managers etc. That is exactly what PARS is doing, and we will see the results as some of these money managers start buying.
PARS is a small company, and its PR efforts can't come close to powerhouses like MSFT, IBM, YHOO and the rest. What do you expect them to do, put a gun to the head of NY Times and make him put them on the front page? Claiming PARS' IR efforts are not good is a false accusation. I know that Gadi spends a good portion of his time on this issue, and remember he has other things to do (like find us a good partner for HU211).
PARS' management is different from most Israeli managements, they don't build huge expectations. Their philosophy is under-estimate and overperform, they don't want high expectations from the get go, that can only lead to trouble (looking at Israeli stocks you can find many examples). I don't mind that the street hasn't "discovered" them yet, as it gives me more chance to buy the stock at these ridiculous prices. You should do the same, instead of complaining, use this inefficiency to you advantage and buy more stock.
PARS did not want to make too many claims when they first presented the HU211 findings, they didn't want to seem like hypsters. They wanted to see how the experts react first. Now, they know that the entire field is excited, and that many opinion leaders think this is exactly what neurosurgeons have been waiting for. Now, they will feel more comfortable being more decisive and optimistic when they speak to media.
PARS will present findings again (with some new data as well) in a conference within a few days. I believe they will sound much more up-beet this time around, and we'll probably see another press release, which will hopefully include quotes from more leading neurosurgeons.
I'm very certain that HU211 will become an FDA approved drug within a couple of years. When that happens, PARS will be able to earn about $1 per share. That means a stock of at least $20. Getting a 10-bagger in 3 years is not too shabby, and I don't see any other stock that can give such a return.
Omer |
